Side-by-side · Research reference
BronchogenvsCartalax
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED16/35 cited
BAnimal-MechanisticHUMAN-REVIEWED10/32 cited
Bronchogen
Tetrapeptide Bioregulator · Khavinson-School
Research models: tissue culture / parenteral
Cartalax
Bioregulator Peptide · Khavinson School
SQ · Protocol Unspecified
01Mechanism of Action
Parameter
Bronchogen
Cartalax
Primary target
Bronchial epithelial cellsKuzubova 2015
Mesenchymal stem cells (MSCs) undergoing chondrogenic differentiationLinkova 2023
Pathway
Tissue-specific bioregulation → epithelial cell differentiation → ciliated cell restoration
Modulation of WNT, ERK-p38, and Smad 1/5/8 signaling pathwaysLinkova 2023
Downstream effect
Reversal of goblet cell hyperplasia, squamous metaplasia elimination, restoration of ciliated epithelium, normalized secretory IgA and surfactant protein B productionKuzubova 2015Titova 2017
Upregulation of chondrogenic genes (COL2, SOX9, ACAN); increased bone mineral density; osteoprotective effects in ovariectomy-induced osteoporosisLinkova 2023Povorozniuk 2007
Feedback intact?
—
—
Origin
Synthetic tetrapeptide (Ala-Glu-Asp-Leu) from Khavinson bioregulator framework
Derived from cartilaginous tissue extracts (Khavinson bioregulator methodology)Povorozniuk 2007
Antibody development
—
—
02Dosage Protocols
Parameter
Bronchogen
Cartalax
Effective concentration (culture)
0.05 ng/mLZakutskiĭ 2006
Demonstrated in organotypic tissue culture of bronchial explants.
—
Treatment duration (animal)
1 month (30 days)Kuzubova 2015Titova 2017
Course duration in rat COPD models.
—
Evidence basis
Animal models (rat) / organotypic cultureTitova 2017Kuzubova 2015Zakutskiĭ 2006
No human clinical trials reported in available literature.
Animal mechanistic studies only
Tissue specificity
Selective for bronchopulmonary tissue
Part of Khavinson organ-specific bioregulator series.
—
Animal model dose
—
Unspecified (cartilaginous tissue extract protocol)
Rat study; extract preparation details not indexed in available abstracts.
Human dosing
—
Not established in PubMed-indexed literature
Russian-tradition protocols exist but lack peer-reviewed Western validation.
03Metabolic / Fat Loss Evidence
Parameter
Bronchogen
Cartalax
Fat loss evidence
—
None — primary target is cartilage and bone tissue, not adipose
04Side Effects & Safety
Parameter
Bronchogen
Cartalax
Animal safety profile
No adverse effects reported in published rat studies
Limited safety data; only animal models available.
—
Human data
Absent — no clinical trials in humans reported
—
Long-term effects
Unknown — maximum study duration 30 days in animals
—
Documented adverse effects
—
None reported in indexed animal studies
Human safety data
—
Not available in PubMed-indexed literature
Absolute Contraindications
Bronchogen
—Cartalax
- ·Unknown due to lack of human clinical trial data
Relative Contraindications
Bronchogen
—Cartalax
- ·Active malignancy (theoretical; peptide bioregulators may influence cell proliferation pathways)
05Administration Protocol
Parameter
Bronchogen
Cartalax
1. Research context only
Bronchogen has been studied exclusively in animal models and organotypic tissue culture. No approved formulation or human administration protocol exists.
Subcutaneous injection typical for Khavinson bioregulators; specific protocols not detailed in indexed literature.
2. Animal model protocol
In rat COPD models, tetrapeptide administered for 30-day course following 60-day NO₂ exposure. Route and exact dosing not specified in abstracts.Titova 2017Kuzubova 2015
Russian-tradition protocols often employ 10-day cycles; precise frequency unspecified in available abstracts.
3. Organotypic culture
Bronchial tissue explants from young (3-week) and aged (18-month) rats cultured in medium containing 0.05 ng/mL bronchogen, demonstrating tissue-specific stimulation.Zakutskiĭ 2006
Lyophilised peptide bioregulators typically stored at 2–8 °C, light-protected. Reconstitution details not indexed.
4. Khavinson bioregulator tradition
Part of Russian peptide bioregulator framework emphasizing tissue-specific low-dose effects. Typically administered parenterally in related peptides from this series.
—